Applications

1250 – Testing of the ALK gene in tumour material from patients with non-small cell lung cancer to determine eligibility for treatment with crizotinib

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Deferred

Application details

Reason for application

-

Service or technology in this application

ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.

Medical condition this application addresses

ALK-positive advanced NSCLC.

Meetings to consider this application

  • PASC meeting: 
    • 12 – 13 April 2012
    • 16 – 17 August 2012
  • ESC meeting: 10 – 11 October 2013
  • MSAC meeting: 28 November 2013